Small lymphocytic lymphoma
Clinical trials for Small lymphocytic lymphoma explained in plain language.
Never miss a new study
Get alerted when new Small lymphocytic lymphoma trials appear
Sign up with your email to follow new studies for Small lymphocytic lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II trial is testing whether a planned dose reduction of the targeted therapy zanubrutinib can maintain control of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) while reducing long-term side effects in patients aged 80 and older who have not yet…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New biologic MK-1045 targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis phase 2 trial tests an experimental biologic called MK-1045 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aims to see if MK-1045 is safe and tolerable, and how many participants respond to treatment. P…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
CLL patients may get a break from daily pills
Disease control Not yet recruitingThis study looks at whether people with chronic lymphocytic leukemia (CLL) who have been in remission for at least two years can safely stop taking their BTK inhibitor medication. The goal is to see how long they stay cancer-free without treatment, and whether stopping improves t…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Three-Drug combo outsmart High-Risk CLL?
Disease control Not yet recruitingThis phase 2 trial is testing whether adding a new immune-boosting drug, epcoritamab, to two existing targeted therapies (ibrutinib and venetoclax) can improve outcomes for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have TP53 …
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo aims to wipe out leukemia cells in First-Line treatment
Disease control Not yet recruitingThis phase 2 trial tests two oral drugs, nemtabrutinib and venetoclax, as a first treatment for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the combination can make cancer cells undetectable in the blood. About 25 adul…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: Jennifer Woyach • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Triple threat: new drug cocktail aims to wipe out CLL/SLL
Disease control Not yet recruitingThis phase 2 trial tests a combination of three drugs—acalabrutinib, venetoclax, and tafasitamab—in 35 people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this mix is safe and can lead to a complete response with very…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA
Phase 2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC